REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Active:	No
Cancer Type:	Bile Duct Cancer Liver Cancer / Hepatoblastoma Solid Tumor Unknown Primary	NCT ID:	NCT04526106
Trial Phases:	Phase I Phase II	Protocol IDs:	RLY-4008-101 (primary) NCI-2020-06870
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Relay Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04526106

Summary

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a
potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic
cholangiocarcinoma (CCA) and other solid tumors. The study consists of 3 parts: a dose
escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.